QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: mol.107.043398v1 73/4/1052    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by King, M. A. Articles by Wyttenbach, A. Search for Related Content PubMed PubMed Citation Articles by King, M. A. Articles by Wyttenbach, A.

Rapamycin Inhibits Polyglutamine Aggregation Independently of Autophagy by Reducing Protein Synthesis

Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (M.A.K., F.H., A.M.T., A.W.); Department of Physiology and Cell Biology, Tokyo Medical and Dental University, Tokyo, Japan (N.M.); and School of Biological Sciences, Neuroscience Group, University of Southampton, Southampton, United Kingdom (S.H., A.W.)

Accumulation of misfolded proteins and protein assemblies is associated with neuronal dysfunction and death in several neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease (HD). It is therefore critical to understand the molecular mechanisms of drugs that act on pathways that modulate misfolding and/or aggregation. It is noteworthy that the mammalian target of rapamycin inhibitor rapamycin or its analogs have been proposed as promising therapeutic compounds clearing toxic protein assemblies in these diseases via activation of autophagy. However, using a cellular model of HD, we found that rapamycin significantly decreased aggregation-prone polyglutamine (polyQ) and expanded huntingtin and its inclusion bodies (IB) in both autophagy-proficient and autophagy-deficient cells (by genetic knockout of the atg5 gene in mouse embryonic fibroblasts). This result suggests that rapamycin modulates the levels of misfolded polyQ proteins via pathways other than autophagy. We show that rapamycin reduces the amount of soluble polyQ protein via a modest inhibition of protein synthesis that in turn significantly reduces the formation of insoluble polyQ protein and IB formation. Hence, a modest reduction in huntingtin synthesis by rapamycin may lead to a substantial decrease in the probability of reaching the critical concentration required for a nucleation event and subsequent toxic polyQ aggregation. Thus, in addition to its beneficial effect proposed previously of reducing polyQ aggregation/toxicity via autophagic pathways, rapamycin may alleviate polyQ disease pathology via its effect on global protein synthesis. This finding may have important therapeutic implications.

Address correspondence to: Dr. Andreas Wyttenbach, Southampton Neuroscience Group, School of Biological Sciences, University of Southampton. Bassett Crescent East, Southampton SO16 7PX, UK. E-mail: aw3{at}soton.ac.uk

This article has been cited by other articles:

				S. Carra, J. F. Brunsting, H. Lambert, J. Landry, and H. H. Kampinga HspB8 Participates in Protein Quality Control by a Non-chaperone-like Mechanism That Requires eIF2{alpha} Phosphorylation J. Biol. Chem., February 27, 2009; 284(9): 5523 - 5532. [Abstract] [Full Text] [PDF]

				M. A. King, C. G. Goemans, F. Hafiz, J. H. M. Prehn, A. Wyttenbach, and A. M. Tolkovsky Cytoplasmic Inclusions of Htt Exon1 Containing an Expanded Polyglutamine Tract Suppress Execution of Apoptosis in Sympathetic Neurons J. Neurosci., December 31, 2008; 28(53): 14401 - 14415. [Abstract] [Full Text] [PDF]